MedPath

NB-UVB and PUVA Vitiligo Study

Phase 4
Completed
Conditions
Vitiligo
Interventions
Other: Phototherapy
Other: Phototherapy and Photochemotherapy
Registration Number
NCT01732965
Lead Sponsor
Henry Ford Health System
Brief Summary

To evaluate if the combination of psoralen plus ultraviolet A and narrowband ultraviolet B is more effective than narrowband ultraviolet B alone in the treatment of vitiligo.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • Vitiligo affecting more than 15% body surface area.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NB-UVB phototherapyPhototherapyNB-UVB alone
phototherapy and photochemotherapyPhototherapy and PhotochemotherapyNB-UVB and PUVA
Primary Outcome Measures
NameTimeMethod
Determine the quantity of repigmentation6 months

Determination the degree of repigmentation measured by the VASI score (Vitiligo area Scoring Index) after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone.

Secondary Outcome Measures
NameTimeMethod
Determine the quality of repigmentation.Study initiation, 3 months and 6 months.

Determination of the color of repigmentation, pattern of repigmentation, and the cessation of spread of vitiligo after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone.

Trial Locations

Locations (1)

Henry Ford Dermatology

🇺🇸

Detroit, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath